Immunotherapy for Pediatric Malignancies

Dr. Juliet Gray is an Associate Professor and Consultant in Paediatric Oncology at the University of Southampton, UK.  She has a strong clinical and research interest in immunotherapy for neuroblastoma, with particular expertise in novel antibody therapies. She leads a translational laboratory research group within the Southampton Cancer Immunology Centre, and is an active member of the UK NCRI Neuroblastoma group and SIOP European Neuroblastoma Research Network (SIOPEN).Aurélien Marabelle, is currently the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy Cancer Center in Villejuif, France. Dr Marabelle is an immunologist and a pediatric oncologist by training. His clinical practice is currently dedicated to Early Phase Clinical trials in Cancer Immunotherapy and his translational research is focused on mechanisms of action of immune targeted therapies. He works as a senior medical oncologist and an investigator in the Drug Development Department (DITEP) directed by Prof Jean-Charles Soria. He is coordinating a team focusing on cancer immunotherapy translational research projects in the INSERM U1015 lab directed by Prof Laurence Zitvogel. Dr Marabelle is a member of the European Society of Medical Oncology (ESMO), the American Association of Clinical Oncology (ASCO), the European Academy of Tumor Immunology (EATI) & the American Association of Cancer Research (AACR).

Introduction to Pediatric Cancer Immunotherapy.- Overcoming immune suppression in the tumor microenvironment: Implications for multi-modal therapy.- Allogeneic stem cell transplantation.- Overview of monoclonal antibody therapies.- Monoclonal Antibodies Targeting Hematological Malignancies.- Monoclonal Antibodies Directly Targeting Antigens on Solid Tumours.- Monoclonal antibodies targeting the immune system.- Adoptive T Cell Therapies for Children's Cancers.- NK Cell and NKT Cell Immunotherapy.- Cancer Vaccines in Pediatrics.- Immune Adjuvants and Cytokine Therapies.- Immune biomarkers in pediatric malignancies.- Future perspectives

"Addressing the major histological, biological, and developmental differences between children and adult cancer patients, this comprehensive book provides up-to-date, state-of-the-art information on immunotherapy for pediatric malignancies. ... The book is intended primarily for pediatric oncologists and physicians, fellows, and interns working in pediatric cancer care. ... this is a great book that is very informative and authoritative and includes experiences from clinicians and scientists working at some of the most renowned cancer centers in the world." (Ravi Salgia, Doody's Book Reviews, August, 2018)

“Addressing the major histological, biological, and developmental differences between children and adult cancer patients, this comprehensive book provides up-to-date, state-of-the-art information on immunotherapy for pediatric malignancies. … The book is intended primarily for pediatric oncologists and physicians, fellows, and interns working in pediatric cancer care. … this is a great book that is very informative and authoritative and includes experiences from clinicians and scientists working at some of the most renowned cancer centers in the world.” (Ravi Salgia, Doody's Book Reviews, August, 2018)